Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101^st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

The following two posters will be presented:

"M402 - A Novel Heparin Sulfate Mimetic Synergizes with Gemcitabine to Improve Survival and Reduce Metastasis and Epithelial-to-Mesenchymal Transition (EMT) in a Genetically Engineered Mouse Model for Pancreatic Cancer" (abstract #LB-43)

-- Poster Session: Sunday, April 18, 2010 from 2:00 PM - 5:00 PM

"M402 - A Novel Heparan Sulfate Proteoglycan Mimetic Targeting Tumor-Host Interactions" (abstract #2269)

-- Poster Session: Monday, April 19, 2010 from 2:00 PM - 5:00 PM